Case Status: Investigations
The Ademi Firm is investigating Metsera (Nasdaq: MTSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.
Shareholders of Metsera will receive $47.50 per share in a transaction with an enterprise value of approximately $4.9 billion. Metsera insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Metsera by imposing a significant penalty if Metsera accepts a competing bid. We are investigating the conduct of the Metsera board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.